X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (66) 66
humans (63) 63
diabetes (31) 31
male (29) 29
female (27) 27
endocrinology & metabolism (24) 24
diabetes mellitus, type 2 - drug therapy (19) 19
hypoglycemic agents - therapeutic use (19) 19
meta-analysis (19) 19
type 2 diabetes (19) 19
adult (18) 18
middle aged (18) 18
analysis (17) 17
medicine, general & internal (17) 17
diabetes mellitus (14) 14
insulin (14) 14
research (14) 14
systematic review (14) 14
care and treatment (13) 13
hyperglycemia (13) 13
peripheral vascular disease (13) 13
treatment outcome (13) 13
clinical trials (12) 12
double-blind (12) 12
risk factors (12) 12
abridged index medicus (10) 10
glucagon (10) 10
internal medicine (10) 10
management (10) 10
medical research (10) 10
medicine & public health (10) 10
drug therapy (9) 9
glucose (9) 9
glycemic control (9) 9
aged (8) 8
efficacy (8) 8
health aspects (8) 8
hemoglobin (8) 8
monocytes (8) 8
randomized controlled trials as topic (8) 8
surgery (8) 8
cardiovascular diseases (7) 7
cardiovascular diseases - prevention & control (7) 7
diabetes mellitus, type 2 - blood (7) 7
hematology (7) 7
insulin resistance (7) 7
medicine, experimental (7) 7
studies (7) 7
type 2 diabetes mellitus (7) 7
atherosclerosis (6) 6
bias (6) 6
cardiovascular disease (6) 6
diabetes mellitus, type 2 - complications (6) 6
diabetes therapy (6) 6
diabetic foot (6) 6
endocrinology (6) 6
hypoglycemia (6) 6
hypoglycemic agents (6) 6
hypoglycemic agents - administration & dosage (6) 6
metaanalysis (6) 6
mortality (6) 6
obesity (6) 6
patients (6) 6
safety (6) 6
therapy (6) 6
add-on (5) 5
blood glucose - drug effects (5) 5
cardiovascular diseases - etiology (5) 5
diabetics (5) 5
diagnosis (5) 5
dipeptidyl peptidase-4 inhibitors (5) 5
evidence-based medicine (5) 5
glucagon-like peptide 1 (5) 5
glycated hemoglobin a - metabolism (5) 5
hypoglycemia - chemically induced (5) 5
medicine (5) 5
metformin (5) 5
monocytes - drug effects (5) 5
peptides (5) 5
pharmacology & pharmacy (5) 5
benzhydryl compounds - therapeutic use (4) 4
blood pressure (4) 4
blood-pressure (4) 4
body weight (4) 4
case-control studies (4) 4
complications and side effects (4) 4
cotransporter 2 inhibitors (4) 4
decision making (4) 4
diabetes mellitus, type 2 - epidemiology (4) 4
gastroenterology & hepatology (4) 4
glucosides - therapeutic use (4) 4
greece - epidemiology (4) 4
guidelines (4) 4
hyperglycemia - drug therapy (4) 4
hypoglycemic agents - adverse effects (4) 4
insulin - therapeutic use (4) 4
mellitus (4) 4
nutrition & dietetics (4) 4
open-label (4) 4
outcomes (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Diabetologia, ISSN 0012-186X, 12/2018, Volume 61, Issue 12, pp. 2461 - 2498
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in... 
Heart failure | Costs | Weight management | Human Physiology | Patient-centred care | Glucose-lowering therapy | Hypoglycaemia | Metabolic Diseases | Internal Medicine | Cardiovascular disease | Chronic kidney disease | Type 2 diabetes mellitus | Guidelines | Medicine & Public Health | MULTIPLE DAILY INJECTIONS | FIXED-RATIO COMBINATION | COTRANSPORTER 2 INHIBITORS | GLARGINE PLUS LIXISENATIDE | RANDOMIZED CONTROLLED-TRIAL | PEPTIDE-1 RECEPTOR AGONISTS | CLINICAL-PRACTICE GUIDELINES | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | ENDOCRINOLOGY & METABOLISM | INTENSIVE MEDICAL THERAPY | CARDIOVASCULAR RISK-FACTORS | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | United States | Cardiovascular Diseases - drug therapy | Europe | Humans | Hyperglycemia - drug therapy | Consensus | Heart Failure - drug therapy | Renal Insufficiency, Chronic - drug therapy | Liraglutide - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Insulin - therapeutic use | Type 2 diabetes | Hyperglycemia | Chronic kidney failure | Cardiac patients | Self-care, Health | Glucose | Business education | Dextrose | Diabetes therapy | Glucagon | Diabetes mellitus | Body weight loss | Management | Coronary artery disease | Sodium | Arteriosclerosis | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Glucagon-like peptide 1 | Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2010, Volume 153, Issue 2, p. 9
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 04/2018, Volume 168, Issue 8, p. JC46
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 04/2018, Volume 168, Issue 8, p. JC46
Once-weekly subcutaneous semaglutide, 0.25 mg for 4 weeks. 0.5 mg for 4 weeks, and 1.0 mg for 48 weeks, by prefilled pen injector [n = 406); or once-weekly... 
Weight control | Medical treatment | Hemoglobin | Diabetes | Drug therapy
Journal Article
Annals of internal medicine, ISSN 0003-4819, 04/2018, Volume 168, Issue 8, pp. JC46 - JC46
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 07/2010, Volume 153, Issue 2, p. JC1
  Tsapas comments on Salpeter et al's study determining whether metformin can increase risk for lactic acidosis compared with placebo or other glucose-lowering... 
MEDICINE, GENERAL & INTERNAL | Acidity | Diabetes | Meta-analysis
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2018, Volume 20, Issue 9, pp. 2255 - 2263
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 08/2018, Volume 169, Issue 3, pp. 165 - 174
Basal insulin analogues aim for protracted glycemic control with minimal adverse effects. To assess the comparative efficacy and safety of basal insulin... 
Type 2 diabetes | Treatment outcome | Usage | Care and treatment | Safety and security measures | Analysis | Research | Insulin | Meta-analysis | Clinical trials | Systematic review | Diabetes
Journal Article
by Hernandez, Adrian F and Green, Fiona and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Michael and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Rosenberg, Anne and Sigmon, Kristina and Sigmon, Kristina N and Somerville, Matthew and Somerville, Matthew C and Thorpe, Karl and Thorpe, Karl M and McMurray, John J V and McMurray, John J.V and Del Prato, Stefano and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Patel, Rajesh and Patel, Vickas and Patel, Prashant and Patel, Rajivkumar and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Harrison, Lindsay and Lopes, Renato and Mathews, Robin and Mehta, Anand and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Deb and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, John and Cooper, Lauren and Sharma, Abhinav and Sharma, Richa and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Wilson, Tim and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and James, Rachel and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Johnson, David and Johnson, Andrew and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Judith and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and ... and Harmony Outcomes Comm Investigator and Harmony Outcomes committees and investigators
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article